GDRX - Let's Play Q&A: Pharma Direct Hits a New Gear

Research evidence excerpt

GDRX - Let's Play Q&A: Pharma Direct Hits a New Gear

arket Cap ($M) $850 erosion to ~5.1 million by year-end, reflecting ongoing uncertainty. Management believes it

ADTV 1,626,450 gained share in a contracting cash-pay market in 2025 and is focused on whether the overall

Shares Out (M) 341 market returns to growth, which would provide incremental upside.

Short Interest Ratio/% Of Float 8.5%

TrumpRx Relationship & Infrastructure Role. GoodRx clarified that it does not have Dividend/Yield $0.00/0.0%

a direct contract with TrumpRx or the administration; instead, agreements exist between Enterprise Value ($M) $1,102 pharma manufacturers and the administration. GoodRx’s role is operational - facilitating

Cash & Equivalents ($M) $236 pricing execution through its infrastructure, including adjudication, pharmacy network

Total Debt ($M) $487 access, and API integrations. The company supports over 125 net-price POS deals, which

have become the primary mechanism for manufacturers to bring pricing to market. Despite

14 Page Document the lack of a formal TrumpRx contract, GoodRx still captures its administrative fee on

transactions routed through its platform.

Reasons for this report Subscription Strategy & GLP-1 Offering. The $39/month weight-loss subscription remains unchanged since launch, with no step-up pricing after the first month - differentiating it

from competitors. Management highlighted strong retention performance, exceeding internal ✓ Earnings Recap

expectations, and emphasized that pricing was carefully chosen to balance affordability, ✓ Updating Estimates

margins, and market share gains. While selective price testing continues, consistency

✓ Management Call Takeaways is central to the brand proposition. More broadly, GoodRx is exploring a reimagined